Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients
Authors:
- 19 May 2017
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 10 (7) , 783-788
Abstract
Background: The pharmacokinetic (PK) profile of tenofovir disoproxil fumarate in Chinese adults infected with HIV is unknown. Methods: A pilot, prospective, open-label study was performed to investigate the steady-state PK profile of tenofovir disoproxil fumarate in 15 Chinese HIV-infected patients among whom eight patients were treated with 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine and 400/100 mg lopinavir/ritonavir, and seven with 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine and 400 mg nevirapine. The plasma concentrations of tenofovir over the 24-h dosing interval were determined by HPLC. The PK parameters were calculated using the non-compartmental model in WinNonlin software. Results: The PK parameters of tenofovir in the 15 patients were determined as follows (mean ± SD): AUC(0-24 h), 4074.7 ± 1551.9 ng•h/mL; Cmax,ss, 447.1 ± 217.4 ng/mL; Ctrough,ss, 98.7 ± 36.7 ng/mL; tmax,ss, 1.3 ± 0.4 h; plasma t1/2, 21.8 ± 7.6 h; and CLss/F, 45.8 ± 13.0 L/h. Conclusion: Tenofovir demonstrated slower elimination rate and increased plasma concentration in Chinese patients compared to previously published data from Caucasian or African subjects, which may be associated with the higher incidences of renal and bone resorption dysfunction observed in our patient population. Clinicians should be cautious of the differing PK characteristics of tenofovir among people of different races.Keywords
Funding Information
- China Ministry of Science and Technology (2012ZX10001-003)
- China Ministry of Health (2010–2012)
- Beijing Science & Technology Commission (Z121100005512027)
This publication has 25 references indexed in Scilit:
- Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIVOsteoporosis International, 2014
- Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter studyBMC Infectious Diseases, 2013
- Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological MonitoringPLOS ONE, 2012
- Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV InfectionPLOS ONE, 2012
- Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteersHIV Medicine, 2009
- Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir-Ritonavir in Adolescents and Young Adults with Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 2008
- Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/RitonavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Pharmacokinetics of Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Saquinavir Mesylate Administered Alone or in Combination at Steady StateAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetic Study of Tenofovir Disoproxil Fumarate Combined with Rifampin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2005
- Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected AdultsAntimicrobial Agents and Chemotherapy, 2001